<DOC>
	<DOCNO>NCT02269046</DOCNO>
	<brief_summary>The purpose study evaluate effect 12 week acupuncture moxibustion compare active control , absolute percent change baseline low-density lipoprotein cholesterol ( LDL-C ) among hyperlipidemia .</brief_summary>
	<brief_title>Acupuncture Moxibustion Hyperlipemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Subject sign informed consent Male female ≥18 ≤75 year age Fasting TG ≤400 mg/dL Fasting LDLC determine central laboratory admission meeting follow LDLC value base risk factor status : 01 Risk Factor Group : LDLC ≥160 mg/dL 2+ Risk Factor Group : LDLC ≥130 mg/dL CHD CHD risk equivalent : LDLC ≥100 mg/dL Major Risk factor : （1）Cigarette smoking ; （2）Hypertension ( BP ≥140/90 mmHg antihypertensive medication ) ; （3）Low HDL cholesterol ( HDLC &lt; 40 mg/dL ) ; （4）Family history premature CHD ( CHD male first degree relative &lt; 55 year ; CHD female first degree relative &lt; 65 year ) ; （5）Age ( men ≥45 year ; woman ≥55 year ) CHD CHD equivalent : （1）Other clinical form atherosclerotic disease ( peripheral arterial disease , abdominal aortic aneurysm , symptomatic carotid artery disease ) ; （2）Diabetes ; （3）Multiple risk factor confer 10year risk CHD &gt; 20 % CHD CHD risk equivalent receive statin therapy , LDLC screen ≤99 mg/dL NYHA II , III IV heart failure , last known leave ventricular ejection fraction &lt; 30 % Uncontrolled cardiac arrhythmia , atrial fibrillation rapid ventricular response , control supraventricular tachycardia past 3 month prior randomization Myocardial infarction , unstable angina , percutaneous coronary intervention ( PCI ) , coronary artery bypass graft ( CABG ) stroke within 3 month prior randomization Planned cardiac surgery revascularization Type 1 diabetes newly diagnose type 2 diabetes poorly control type 2 diabetes Uncontrolled hypertension define sit systolic blood pressure ( SBP ) &gt; 160 mmHg diastolic BP ( DBP ) &gt; 100 mmHg Subjects take red yeast rice , niacin &gt; 200 mg/d , omega3 fatty acid &gt; 1000 mg/d prescription lipidregulating drug statin ezetimibe , fibrates derivative , bileacid sequestering resin last 6 week prior LDLC screen Subjects take systemic cyclosporine , systemic steroid , vitamin A derivative retinol derivative treatment dermatologic condition last 3 month prior LDLC screen Hyperthyroidism hypothyroidism Moderate severe renal dysfunction Active liver disease hepatic dysfunction CK &gt; 3 time ULN screen end lipid stabilization period , confirm repeat measurement least 1 week apart Known active infection major hematologic , renal , metabolic , gastrointestinal endocrine dysfunction judgment investigator Deep vein thrombosis pulmonary embolism within 3 month prior randomization Current therapeutic anticoagulation vitamin K antagonist , heparin , lowmolecular weight heparin , direct thrombin inhibitor Currently enrol another investigational device drug study Female subject pregnant breast feeding period History malignancy ( except nonmelanoma skin cancer , cervical insitu carcinoma , breast ductal carcinoma situ , stage 1 prostate carcinoma ) Known sensitivity product administer dose Subjects could n't provide write informed consent and/or comply require study procedure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>acupuncture</keyword>
	<keyword>moxibustion</keyword>
	<keyword>hyperlipidemia</keyword>
	<keyword>effectiveness</keyword>
</DOC>